AstraZeneca announced the successful completion of the acquisition of Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering AstraZeneca’s cell therapy ambition.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (œGracell or the œCompany, NASDAQ: GRCL), a global clinical-stage biopharmaceutical...
Gracell Announces FDA Clearance of IND Application for Ph 1 of FasTCAR-T GC012F
AstraZeneca to buy China`s Gracell Biotechnologies in $1.2 bln deal
Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in...
SAN DIEGO — Big Pharma companies aren’t the only players at #ASH23. Many biotechs — including Autolus and Gracell — who are looking to make their mark in hematology and blood cancers are also here in California to present CAR-T treatment data.
Minimal residual disease negativity (MRD-) observed in all treated patients in the ongoing study, with 95% (21/22) achieving stringent complete response (sCR) through a median follow-up of 18.8 months...
Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and wider depletion of disease-causing antibody secreting cells...
Presentation to focus on application of next-generation CAR-T cell therapy technologies for treatment of autoimmune disease Gracell to highlight translational research supporting CD19/BCMA...
Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) Expect to commence Phase 1/2 clinical trial in...